Timothy Smith on AI, Data, and Drug Discovery at Takeda
May 14, 2026
In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Timothy Smith, Senior Director of AI Innovation and Head of the Data Sciences Communities at Takeda, to explore how AI is transforming drug discovery and development, why trust and governance are still major hurdles, and why the biggest bottleneck in pharma innovation might not be technology but people.
Pharma Sessions provides general insights into the pharmaceutical and life sciences industry through conversations with its guests. The content shared in this podcast is for informational purposes only and should not be considered medical, legal, regulatory, or financial advice.
The use of any information discussed in this episode or materials linked from the podcast is at the listener’s own risk. The views and opinions expressed by guests are their own and do not necessarily reflect the views of Jonathan Kaskey, Pharma Sessions, its sponsors, or affiliated organizations.
Any reference to specific products, companies, regulatory pathways, or commercial strategies is provided for discussion purposes only and does not constitute endorsement or validation by the podcast, host, or sponsors.
In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Timothy Smith, Senior Director of AI Innovation and Head of the Data Sciences Communities at Takeda, to explore how AI is transforming drug discovery and development, why trust and governance are still major hurdles, and why the biggest bottleneck in pharma innovation might not be technology but people.
What You’ll Learn:
- Using CIA demographic data to model COVID risk by country in Tim's first week at Takeda
- Why data lakes often fail despite massive investment
- How legal document review is a window into what's coming for all knowledge workers
- Why even the CEO of an automated compound discovery company still won't cut medicinal chemists out of the process
Timothy Smith, PhD, is the Senior Director of AI Innovation and Head of the Data Sciences Communities at Takeda, bringing over two decades of experience at the intersection of chemistry, toxicology, and advanced analytics. With a PhD in neurotoxicology from Cornell University and a pioneering track record as an early adopter of machine learning in pharma, Timothy has evolved from wet-lab researcher to enterprise innovation strategist.
Pharma Sessions provides general insights into the pharmaceutical and life sciences industry through conversations with its guests. The content shared in this podcast is for informational purposes only and should not be considered medical, legal, regulatory, or financial advice.
The use of any information discussed in this episode or materials linked from the podcast is at the listener’s own risk. The views and opinions expressed by guests are their own and do not necessarily reflect the views of Jonathan Kaskey, Pharma Sessions, its sponsors, or affiliated organizations.
Any reference to specific products, companies, regulatory pathways, or commercial strategies is provided for discussion purposes only and does not constitute endorsement or validation by the podcast, host, or sponsors.
Episode Resources:
Episode Resources:
Pharma Sessions is handcrafted by our friends over at: fame.so